Ask AI
ProCE Banner Activity

EDGE-Gastric Arm A1 Update: Phase II Trial of Domvanalimab, Zimberelimab, and FOLFOX in Previously Untreated Advanced HER2-Negative GC/GEJC/EAC

Conference Coverage
Slideset

An updated analysis from arm A1 of the phase II EDGE-Gastric trial exploring treatment with domvanalimab plus zimberelimab and FOLFOX demonstrated promising efficacy with a safety profile consistent with anti–PD-1 plus chemotherapy in patients with previously untreated advanced gastric cancers, gastroesophageal junction adenocarcinoma, and esophageal adenocarcinoma.

Released: October 29, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Incyte, and Lilly.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Incyte

Lilly